Analysis of peripheral lymphocytes of lymphoma patients for daunomycin (DNR) retention and cell differentiation antigens (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Analysis of peripheral lymphocytes of lymphoma patients for daunomycin (DNR) retention and cell differentiation antigens (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A1846 1994. Unique Identifier : AIDSLINE ICDB/94603532
Samy TS; Byrnes J; Krishan A; Harrington WJ Jr; Byrnes G; Wellham LL; Sauerteig A; Fletcher MA; University of Miami School of Medicine, Miami, FL 33136

Abstract: The lymph node cells and peripheral blood lymphocytes of lymphoma patients were analyzed for cellular DNR retention, response to efflux blockers and expression of human differentiation antigens. Extensive heterogeneity in cellular DNR retention was seen in lymphocytes in 10/66 patients. Cellular DNR retention could be significantly increased by coincubation with 25 uM prochlorperazine (6/10), 10 uM verapamil (2/10) or 20 uM dipyridamole (1/10). Analysis for differentiating antigen expression showed baseline CD2, CD3, CD8 and CD25 counts significantly associated with increased survival of HIV patients while CD4, CD4 subset and B cell counts were not. Furthermore, patients with lymphocytes of CD8 counts greater than 1000 responded to chemotherapy suggesting that CD8 counts may be an important predictor for HIV associated lymphoma. These studies underscore the importance of cellular markers in diagnosis of lymphoma and suggest the use of appropriate efflux blocker or drug retention and a cytokine for CD8 cell enrichment.
Keywords: Antigens, CD/*ANALYSIS Daunorubicin/*PHARMACOKINETICS Human Lymphocyte Subsets/IMMUNOLOGY/*METABOLISM Lymphocytes/IMMUNOLOGY/*METABOLISM Lymphoma/BLOOD/*DRUG THERAPY/IMMUNOLOGY/*METABOLISM Lymphoma, AIDS-Related/BLOOD/*DRUG THERAPY/IMMUNOLOGY Prognosis ABSTRACTKWDantigens,cd/KWDanalysisdaunorubicin/KWDpharmacokineticshumanlymphocytesubsets/immunology/KWDmetabolismlymphocytes/immunology/KWDmetabolismlymphoma/blood/KWDdrugtherapy/immunology/KWDmetabolismlymphoma,aids-related/blood/KWDdrugtherapy/immunologyprognosisabstract
941230
M94C4325

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .